June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
Towards Corneal Gene Therapy in the Aniridia Mouse Model Pax6Sey/+
Author Affiliations & Notes
  • Elizabeth M Simpson
    Centre for Molecular Medicine and Therapeutics (CMMT), University of British Columbia, Vancouver, British Columbia, Canada
    Department of Medical Genetics, University of British Columbia, Vancouver, British Columbia, Canada
  • Siu Ling Lam
    Centre for Molecular Medicine and Therapeutics (CMMT), University of British Columbia, Vancouver, British Columbia, Canada
  • Andrea Korecki
    Centre for Molecular Medicine and Therapeutics (CMMT), University of British Columbia, Vancouver, British Columbia, Canada
  • Beatrice M Tam
    Department of Ophthalmology and Visual Sciences, University of British Columbia, Vancouver, British Columbia, Canada
  • Orson L Moritz
    Department of Ophthalmology and Visual Sciences, University of British Columbia, Vancouver, British Columbia, Canada
  • Jack Hickmott
    Centre for Molecular Medicine and Therapeutics (CMMT), University of British Columbia, Vancouver, British Columbia, Canada
    Department of Medical Genetics, University of British Columbia, Vancouver, British Columbia, Canada
  • Footnotes
    Commercial Relationships   Elizabeth Simpson, None; Siu Ling Lam, None; Andrea Korecki, None; Beatrice Tam, None; Orson Moritz, None; Jack Hickmott, None
  • Footnotes
    Support  Brain Canada, Quebec Consortium for Drug Discovery (CQDM), Canadian Institutes of Health Research, Sharon Stewart Aniridia Research Trust, Foundation Fighting Blindness – Canada, National Science and Engineering Research Council, Studentships from the University of British Columbia
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 4481. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Elizabeth M Simpson, Siu Ling Lam, Andrea Korecki, Beatrice M Tam, Orson L Moritz, Jack Hickmott; Towards Corneal Gene Therapy in the Aniridia Mouse Model Pax6Sey/+. Invest. Ophthalmol. Vis. Sci. 2017;58(8):4481.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Aniridia is a rare autosomal dominant disorder caused by mutations in PAX6 (Paired Box 6). Although named for lack of iris, aniridia is a panocular disorder, with vision loss attributable to three main causes: 1) hypomorphic fovea, 2) progressive corneal clouding, and 3) progressive glaucoma. Current treatments may delay vision loss, but do not prevent the blindness experienced by most people with aniridia. Gene therapy is a promising treatment strategy that may delay, or even prevent, vision loss. Here we focus on gene therapy for the corneal pathology.

Methods : EmGFP (emerald GFP), PAX6, 3xFLAG/PAX6, and PAX6/3xFLAG mRNAs were injected into Xenopus laevis embryos, which were fixed and examined 14 days later. Additionally, EmGFP and 3xFLAG/PAX6 constructs, driven by smCBA (ubiquitous) or a human MiniPromoter (targeted to the cornea) were cloned into a custom rAAV genome, and packaged into rAAV9 at the University of Pennsylvania Vector Core. Viruses were introduced into wild-type and Pax6Sey/+ mice using several different injections routes. Mouse eyes were longitudinally scored for corneal opacification and then harvested by enucleation, and fixed in 4% paraformaldehyde. Cryosections were stained with antibodies against EmGFP, PAX6, and FLAG tag for immunofluorescent analysis.

Results : Since human and mouse PAX6 are indistinguishable by immune detection, we required a tagged version of PAX6 that did not jeopardize PAX6 in vivo function. Thus, we tested PAX6 fused to either amino- or carboxyl-terminal 3xFLAG for the ability to generate ectopic eye structures in X. laevis tadpoles. PAX6 and 3xFLAG/PAX6 mRNA drove similar ectopic eye formation, suggesting that this amino-terminal 3xFLAG tag did not disrupt PAX6 function. Delivery of rAAV to the cornea was then explored using topical, intravitreal, intravenous, and subconjunctival routes with ssAAV9 smCBA-EmGFP-WPRE and ssAAV9 Ple253-EmGFP-WPRE. The MiniPromoter Ple253 was derived from the human PITX3 gene and had previously shown, using a different methodology, to express in the corneal stroma (de Leeuw et al., 2016). In this study, stromal expression was achieved with both intravenous and subconjunctival routes.

Conclusions : These results have laid the foundation for rAAV9 delivery of in vivo functional 3xFLAG/PAX6, with either a ubiquitous or cell-type restricted promoter, by either intravenous or subconjunctival routes, to treat corneal pathology in Pax6Sey/+ mice.

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×